Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GPhA Faces Transition After CEO Jaeger Resigns

This article was originally published in The Pink Sheet Daily

Executive Summary

With a smaller membership and a challenging new biosimilars pathway, association gears up for user fee negotiations with FDA.

You may also be interested in...



Kathleen Jaeger Joins NACDS In Pharmacy And Patient Advocacy Role

New position is first time Jaeger has not had CEO in her title since 2002. She also takes on presidency of NACDS Foundation.

Former GPhA Head Kathleen Jaeger To Take Over As CEO Of NCPA

Jaeger takes on role at National Community Pharmacists Association on Nov. 1, 2010, as the organization works with CMS on Medicaid generic pharmacy reimbursement regulations.

Former GPhA Head Kathleen Jaeger To Take Over As CEO Of NCPA

Jaeger takes on role at National Community Pharmacists Association on Nov. 1, 2010, as the organization works with CMS on Medicaid generic pharmacy reimbursement regulations.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel